Mineralys Therapeutics, Inc.MLYSNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank80
3Y CAGR+71.3%
5Y CAGR+122.7%
Year-over-Year Change
Research and development spending
3Y CAGR
+71.3%/yr
Annual compound
5Y CAGR
+122.7%/yr
Recent deceleration
Percentile
P80
Within normal range
vs 5Y Ago
54.8x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $132.01M | -21.7% |
| 2024 | $168.58M | +139.6% |
| 2023 | $70.36M | +168.0% |
| 2022 | $26.25M | +61.0% |
| 2021 | $16.31M | +576.4% |
| 2020 | $2.41M | - |